drugset / Trial / NCT05074940

Amivantamab in Adenoid Cystic Carcinoma

NCT05074940

Phase 2 Active not recruiting 21 enrolled Trisha Wise-Draper
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Timeline

Start
2022-08-05
Primary completion
2026-03-02
Completion
2028-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Amivantamab Monoclonal antibody 1050 mg Intravenous
Subject Amivantamab Monoclonal antibody 1400 mg Intravenous

Indications